MedTrace Logo

Optive Brand For Day And Night Dry Eye Management

NCT03208673 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2019-06-20

Study results available
· View outcomes & findings →

Summary

This is an open label study of Optive eyedrops and gel combination for day and night dry eye management

Conditions

  • Dry Eye

Interventions

DEVICE

Optive® Fusion + Optive® Gel Drop

Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Sameena Haque · Allergan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-03
Primary Completion
2017-09-06
Completion
2017-09-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208673 on ClinicalTrials.gov